Black Swan og Danmark?

Viser 4 indlæg - 1 til 4 (af 4 i alt)
  • Forfatter
    Indlæg
  • #4012
    Carsten Levin
    Deltager

    Har Black Swan projektet og deres meget aggressive fokus på nye og mere præcise analyser væres behandlet af fagfolk på tidligere temadage her i Danmark eller ved andre danske arrangementer?

    Er danske hospitaler involveret i de nye langt mere præcise undersøgelser og søgning efter resttilstedeværelse af myelomatose celler efter behandling?

    Og er den meget optimistiske og helbredelsessøgende stil man møder på myeloma.org og især vedr. Black Swan projektet et reelt udtryk for nybrydning indenfor området, eller er det mere et spørgsmål om stil og kulturforskelle?
    Jeg håber selvfølgelig det første, men som læg føler jeg behov for at få udlagt teksterne af fagfolk og eksperter.

    Se også
    http://myeloma.org//MtEntryPage.action?source=/imf_blogs/myeloma_voices/2014/07/frontline-therapy-and-mrd-exciting-new-data-from-france.html

    #4019
    Carsten Levin
    Deltager

    Er der ingen andre, og ingen fagfolk/specialister med her på forum?

    #4025
    Carsten Levin
    Deltager

    Hvor langt er man med disse nye analysemetoder I Danmark, og hvad er holding og respons til den meget proaktive holdning til behandling og forholden sig til “minimal residual disease

    http://www.mpatient.org/dr-stephen-harding-hevylite/
    http://en.m.wikipedia.org/wiki/Minimal_residual_disease

    Dr. Stephen Harding
    The Binding Site Group
    Interview Date: July 18, 2014

    Summary

    No myeloma patient wants to hear the word “relapse,” but how can we identify it early so it can be treated? A new FDA approved test called Hevylite® is now available that can pick up myeloma growth before it is seen in the standard SPEP and IFE tests. This new test can also help identify minimal residual disease, even if patients are considered to be have a complete response (CR) or stringent complete response (sCR) using the traditional tests. A test called Freelite* was the first to help myeloma patients identify “normal” and “abnormal” free light chains (kappa and lambda) and the ratio between the two. The Hevylite test expands our knowledge to also tell us how the immune system is responding – is it still suppressed or is it bouncing back? The Hevylite test looks at the heavy part of the chain (IgG, IgA, IgM), immunoglobulins which protect agains bacterial and viral infections. Even small amounts of abnormal light chains can be bad for the immune system and this new test can help patients tell how their myeloma is responding to treatment and how their immune system is recovering (or not). In this show, Dr. Stephen Harding of The Binding Site Group in the UK gives great detail about the use and benefits of the Hevylite test and how it is entering the clinic. This test is now available at the Mayo Clinic and LabCorp and its use is expected to become a regular tool in monitoring myeloma and in testing for minimal residual disease.

    • Dette svar blev ændret 7 år, 11 måneder siden af Carsten Levin.
    #4027
    Carsten Levin
    Deltager

    OUTSTANDING Survival Rates For High Risk Multiple Myeloma At Emory! Is Atlanta The New Little Rock For High Risk Myeloma?

    OUTSTANDING Survival Rates For High Risk Multiple Myeloma At Emory! Is Atlanta The New Little Rock For High Risk Myeloma?
    BY GARY PETERSEN
    If you missed Emory’s Dr. Sagar Lonial’s broadcast on High Risk Myeloma, you missed an excellent and informative program. You can still hear a rebroadcast of the program if you CLICK HERE!
    I do think the major takeaway from Dr. Lonial’s presentation was the excellent results he and his team at Emory in Atlanta have achieved with the high risk group of patients. At 3 years 93% of patients were alive vs. the numbers frequently quoted as 50% survival at 2 years. It was my previous thinking either Mayo Scottsdale or UAMS would be the center to unlock a major breakthrough for high risk multiple myeloma treatment. UAMS which has had such remarkable success in the treatment of low risk disease has not been able to repeat this for high risk myeloma and quotes their average life expectancy of 2 years for the high risk cohort of patients.

Viser 4 indlæg - 1 til 4 (af 4 i alt)
  • Forummet 'Debat' er lukket for nye emner og svar.